Skip to main content
. 2021 Jul 1;9:701504. doi: 10.3389/fbioe.2021.701504

FIGURE 3.

FIGURE 3

Peptide-mediated polymeric micelles for therapeutic applications. (A) Schematics of the preparation of pep2 modified DSPE-PEG2000 micelles. (B) The binding affinities of micelles with or without pep2 modification to HepG2 tumor cells, quantified by flow cytometry. (C) MFIs of HepG2 cells treated by Free doxorubicin, Micelle-doxorubicin, or pep2-Micelle-doxorubicin at equivalent concentrations of doxorubicin (Zheng et al., 2021). Significance (**p < 0.01) was calculated relative to M-Dox. Copyright 2021 Elsevier. (D) Transcytosis of modified micelles in BBB/U87 model in vitro. Penetration of different micelles in the BBTB/U87 tumor spheroid coculture model with or without preincubation were examined by a confocal microscope. L-AE: L-(FALGEA); D-AE: D-(FALGEA); RI-AE: D-(AEGLAF). (E) The fluorescence intensity of different micelles in tumor and organs were identified by semiquantitative ROI analysis (Mao et al., 2017). Copyright 2017 American Chemical Society. ** and *** indicate p < 0.01 and p < 0.001, respectively. (F) Schematic illustration of the MMP-2-responsive polymeric micelle (Barve et al., 2020). Copyright 2020 Elsevier.